Indianapolis-based Eli Lilly and Co. today said it is offering buyouts to its U.S. sales force,
with hopes of trimming about 300 sales representatives before a sales restructuring set to begin in January, Reuters reported.
A company spokesman told Reuters about 4,000 Lilly employees will be eligible for the program.
to lower our headcount ahead of the restructuring and get us closer to the desired number,” Lilly spokesman Ed Sagebiel told
He said the offers have been extended to representatives in the company’s U.S. diabetes, neuroscience and
osteoporosis sales force.
The restructuring, to be announced in November and begin in January, will reduce the size
of Lilly’s sales territories. Smaller territories, each with one sales representative, would allow a better focus on the fewer
doctors within each of the tapered regions, Sagebiel told Reuters.
The reductions also are a response to the scheduled
2011 U.S. patent expiration on Lilly’s best-selling Zyprexa schizophrenia drug, Sagebiel confirmed.
The company needs
to replace nearly 60 percent of the revenue it will lose between 2011 and 2014 when patents on Zyprexa and other top drugs
become available to cheaper generic competitors.